manilatimes24m
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients. SANTA ANA, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen” or the ...
Rolling Out51m
Discover the serious health conditions that triggers stroke
Discover how hypertension, diabetes, atrial fibrillation, high cholesterol, and obesity increase stroke risk, and learn ...